SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
09. Juli 2024 02:00 ET
|
SciRhom GmbH
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary...
Evoke Pharma Announces Closing of $7.5 Million Public Offering
14. Februar 2024 07:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
09. Februar 2024 07:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
DIG raises $65 million in Series F Funding Round from New & Existing Investors with Progressive Vision
27. Oktober 2021 10:46 ET
|
DIG
New York, NY, Oct. 27, 2021 (GLOBE NEWSWIRE) -- DIG, the vegetable-centric, multi-format restaurant group announces its series F raise of $65 million, returning to growth with an industry-leading...
Evergold Signs Definitive Agreement to Option the Rockland Gold-Silver Property, Nevada
16. Februar 2021 07:00 ET
|
Evergold Corp.
TORONTO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evergold Corp. (TSX-V: EVER, OTC: EVGUF, WKN: A2PTHZ) (“Evergold” or the “Company”) is pleased to announce, further to its news release dated January 11,...
Vitality Biopharma Retains DelMorgan & Co. to Explore Strategic Alternatives
25. September 2020 09:00 ET
|
Vitality Biopharma, Inc
CLEVELAND, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a drug development company dedicated to unlocking the unique therapeutic powers of...
Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants
10. Oktober 2018 16:01 ET
|
Histogenics Corporation
WALTHAM, Mass., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the closing of its...
Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants
05. Oktober 2018 08:10 ET
|
Histogenics Corporation
WALTHAM, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an...
Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants
04. Oktober 2018 16:01 ET
|
Histogenics Corporation
WALTHAM, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced that it intends to...
Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock
22. Januar 2018 18:59 ET
|
Histogenics Corporation
WALTHAM, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an...